Saturday August 25 2012 Investors are increasingly betting that Irish drug company Elan won't be sold even after it spins off its cash-hungry drug- development business. Data compiled by Bloomberg shows that the ratio of outstanding so-called puts to sell US-listed shares in Elan compared with calls...
FULL ARTICLE AT Independent